Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: AtriCure Inc., 3 years.
AtriCure Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
AtriCure Inc. May 18, 202697.2%
-
AtriCure Inc. May 19, 202591.4%
-
AtriCure Inc. May 13, 202495.5%
-
AtriCure Inc. May 25, 202395.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 18, 2026 | AtriCure Inc. | Grant or award | +6,144 | — | — |
| Nov 12, 2025 | Gilead Sciences Inc. | Option exercise | +17,181 | $75.12 | $1,290,637 |
| Nov 12, 2025 | Gilead Sciences Inc. | Open-market sale | −17,181 | $124.00 | $2,130,444 |
| Nov 12, 2025 | Gilead Sciences Inc. | Option exercise | +35,965 | $60.75 | $2,184,874 |
| Nov 12, 2025 | Gilead Sciences Inc. | Open-market sale | −35,965 | $122.30 | $4,398,520 |
| Nov 12, 2025 | Gilead Sciences Inc. | Option exercise | +500 | $60.75 | $30,375 |
| Nov 12, 2025 | Gilead Sciences Inc. | Open-market sale | −500 | $122.90 | $61,450 |
| Oct 25, 2025 | Gilead Sciences Inc. | Option exercise | +515 | — | — |
| Oct 25, 2025 | Gilead Sciences Inc. | Shares withheld for tax | −241 | $120.94 | $29,147 |
| Sep 10, 2025 | Gilead Sciences Inc. | Option exercise | +1,315 | — | — |
| Sep 10, 2025 | Gilead Sciences Inc. | Shares withheld for tax | −634 | $115.25 | $73,069 |
| Jul 25, 2025 | Gilead Sciences Inc. | Option exercise | +514 | — | — |
| Jul 25, 2025 | Gilead Sciences Inc. | Option exercise | +8,229 | — | — |
| Jul 25, 2025 | Gilead Sciences Inc. | Shares withheld for tax | −3,823 | $116.20 | $444,233 |
| Jun 10, 2025 | Gilead Sciences Inc. | Option exercise | +1,313 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.